Advice

following an abbreviated submission

palonosetron (Aloxi®) is accepted for use within NHS Scotland.

Indication under review: prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients 1 month of age and older.

A phase III double blind study demonstrated non-inferiority of palonosetron to another 5-HT3 antagonist in paediatric patients.

Download detailed advice50KB (PDF)

Download

Medicine details

Medicine name:
palonosetron (Aloxi)
SMC ID:
1073/15
Indication:
Prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients 1 month of age and older.
Pharmaceutical company
Chugai Pharma UK Ltd
BNF chapter
Central nervous system
Submission type
Abbreviated
Status
Accepted
Date advice published
10 August 2015